Compare IDEXX Laboratories, Inc. (IDXX) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Noble Corporation plc — how do they compare? IDEXX Laboratories, Inc. trades at $558.86 (market cap $44.48B), while Noble Corporation plc trades at $41.66 (market cap $6.48B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.9× Noble Corporation plc's market cap, and Noble Corporation plc pays a 4.93% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | NE | |
|---|---|---|
Market Cap | $44.48B | $6.48B |
Sector | Health | Technology |
52-Week High | $766.68 | $54.37 |
52-Week Low | $520.87 | $25.70 |
Enterprise Value | $45.38B | $7.73B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Noble Corporation (NE) trades at $40.60, down 2.17% today, with mixed technical signals showing a bullish moving average trend but bearish oscillators. The company maintains solid fundamentals with a $3.29B revenue in 2025 and a net income margin of 7.17%, supported by recent contract wins like the $136.2M Brunei drilling deal. Cash flow remains positive, and a $0.50 dividend was recently declared, payable in June 2026.
The outlook is cautiously optimistic with a consensus price target of $49.75 offering 22.5% upside, though recent earnings misses and competitive pressures in offshore drilling pose risks. Analyst sentiment is divided with 31% buy ratings, reflecting confidence in Noble's high-specification rig fleet and contract backlog, balanced by execution challenges and oil price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
